BioSpace News Archive

Lysogene, a phase 3 gene therapy platform company targeting central nervous system diseases, reports positive biomarker data from the ongoing AAVance clinical trial with LYS-SAF302 for the treatment of MPS IIIA as well as favorable safety data from the ongoing adaptative clinical trial with LYS-GM101 for the treatment of GM1 gangliosidosis.

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced that its liquid biopsy focused subsidiary Inivata Limited has announced clinical validation data for its RaDaRTM liquid biopsy test in head and neck squamous cell carcinoma.

Biotage has managed to deal with the global challenges in the supply chain and ended 2021 with another sales record in the fourth quarter.

During the fourth quarter 2021, Alligator reached several key milestones in our pre-clinical, clinical, and partnered programs.

Photocure ASA, The Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals has obtained the Phase III clinical trial application approval from the National Medical Products Administration of China for Hexvix®.

Humanigen, Inc. announced that Timothy E. Morris, COO/CFO, will be presenting at the upcoming 2022 BIO CEO & Investor Conference being held at the Marriott Marquis in NYC on February 14-15 and virtually through the 17th.

TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financial and operating results for its third fiscal quarter ended December 31, 2021.

Immunocore Holdings Plc announced that management will participate in the virtual 11th Annual SVB Leerink Global Healthcare Conference.

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced its pivotal Phase 2/3 Illuminate trial of sepofarsen for the treatment of CEP290-mediated Leber congenital amaurosis 10 (LCA10) did not meet its primary endpoint of Best Corrected Visual Acuity (BCVA) at Month 12.

Prelude Therapeutics Inc., a clinical-stage precision oncology company, announced that Kris Vaddi, PhD, Chief Executive Officer, will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18 at 1:40 p.m. ET.